The anti-EGFR-modified SPIONs developed by Shahbazi-Gahrouei et al. [119] demonstrated excellent tumor accumulation characteristics in lung cancer models, but the targeting efficiency observed in preclinical studies is often difficult to replicate in humans. This evidence concerns the gene EGFR and lung carcinoma.